Perrigo has announced the immediate sale of its UK-based liquid generics subsidiary Rosemont Pharmaceuticals to local private equity player Inflexion for £156m ($195m) in cash, as the firm continues to move away from the prescription generics space to become chiefly a consumer-focused player.
The deal to was “signed and closed on the same day,” Perrigo said, with president and CEO Murray Kessler describing it as “an example of Perrigo’s commitment to our transformation to a consumer-focused